Notice to Readers: Updated Guidelines for the
Use of Rifamycins for the Treatment of Tuberculosis Among
HIV-Infected Patients Taking Protease Inhibitors or Nonnucleoside
Reverse Transcriptase Inhibitors - MMWR 2004; 53 (No. 2) www.cdc.gov/mmwr/preview/mmwrhtml/mm5302a6.htm
Update: Adverse Event Data and Revised American
Thoracic Society/CDC Recommendations Against the Use of
Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis
Infection. MMWR 2003; 52 (No. 31). www.cdc.gov/mmwr/preview/mmwrhtml/mm5231a4.htm
Transmission of Mycobacterium Tuberculosis Associated with
Failed Completion of Treatment for Latent Tuberculosis Infection
- Chickasaw County, Mississippi, June 1999-March 2002 www.cdc.gov/mmwr/preview/mmwrhtml/mm5211a3.htm
MMWR: Public Health Dispatch: Update: Fatal and
Severe Liver Injuries Associated with Rifampin and Pyrazinamide
Treatment for Latent Tuberculosis Infection www.cdc.gov/mmwr/preview/mmwrhtml/mm5144a4.htm
Updated Guidelines for the Use of Rifabutin or
Rifampin for the Treatment and Prevention of Tuberculosis
Among HIV-Infected Patients Taking Protease Inhibitors or
Nonnucleoside Reverse Transcriptase Inhibitors - MMWR 2000;
49 (No. 9) www.cdc.gov/mmwr/preview/mmwrhtml/mm4909a4.htm
Prevention and Treatment of Tuberculosis among
Patients Infected with Human Immunodeficiency Virus: Principles
of Therapy and Revised Recommendations - MMWR 1998; 47 (No.
RR-20) www.cdc.gov/mmwr/preview/mmwrhtml/00055357.htm
Released September 2005
Centers for Disease Control and Prevention
National Center for HIV, STD, and TB Prevention
Division of Tuberculosis Elimination - http://www.cdc.gov/tb
Please send comments/suggestions/requests
to: tbinfo@cdc.gov, or to
CDC/Division of Tuberculosis Elimination
Communications and Education Branch
1600 Clifton Rd., NE - Mailstop E-10, Atlanta, GA 30333